股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 224,519,800 | RMB | | 1 RMB | | 224,519,800 | | 增加 / 減少 (-) | | | 33,677,800 | | | RMB | | 33,677,800 | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. ...

Market Overview - The FTSE China A50 Index components showed mixed performance with sectors like home appliances, liquor, and non-ferrous metals rising, while sectors such as securities, consumer electronics, and logistics declined [1]. Sector Performance Home Appliances - Gree Electric Appliances had a market capitalization of 259.96 billion, with a trading volume of 25.10 billion and an increase of 0.96 (+2.11%) [3]. - Haier Smart Home reported a market cap of 240.01 billion, with a trading volume of 19.79 billion and an increase of 0.82 (+3.31%) [3]. Liquor Industry - Kweichow Moutai had a market capitalization of 1,770.74 billion, with a trading volume of 36.89 billion and an increase of 4.50 (+0.32%) [3]. - Wuliangye Yibin reported a market cap of 214.25 billion, with a trading volume of 11.55 billion and an increase of 1.20 (+0.69%) [3]. Non-Ferrous Metals - The sector showed positive performance, contributing to the overall rise in the index [1]. Securities - CITIC Securities had a market capitalization of 404.30 billion, with a trading volume of 10.59 billion and a decrease of 0.11 (-0.40%) [4]. - Guotai Junan Securities reported a market cap of 338.49 billion, with a trading volume of 15.74 billion and a decrease of 0.07 (-0.36%) [4]. Consumer Electronics - Industrial Fulian had a market cap of 420.21 billion, with a trading volume of 24.20 billion and a decrease of 0.24 (-1.12%) [4]. - Luxshare Precision reported a market cap of 245.97 billion, with a trading volume of 17.15 billion and a decrease of 0.79 (-2.28%) [4]. Logistics - SF Holding had a market capitalization of 272.79 billion, with a trading volume of 17.11 billion and a decrease of 1.51 (-0.67%) [4]. Energy Sector - China Shenhua Energy had a market cap of 190.41 billion, with a trading volume of 8.45 billion and an increase of 0.60 (+1.47%) [3]. - China Petroleum & Chemical Corporation reported a market cap of 1,573.98 billion, with a trading volume of 6.26 billion and a decrease of 0.04 (-0.46%) [3].

Group 1 - The Hong Kong IPO market has experienced explosive growth in the first half of the year, with 43 new listings and a total fundraising amount of HKD 1,067.14 billion, surpassing the total for the entire year of 2024 [2][3][4] - Hong Kong has regained its position as the global leader in IPO fundraising, accounting for 24% of the global total, surpassing both NASDAQ and NYSE [2][3] - The "A+H" listing model, where companies list on both the A-share and H-share markets, has gained popularity, with notable companies like CATL and Hengrui Medicine leading the fundraising efforts [4][5][9] Group 2 - The consumer and hard technology sectors have emerged as significant drivers of IPO activity, with biotech and health, retail, and consumer industries leading in the number of listings [3][6] - There is a notable increase in the number of companies applying for IPOs, with over 180 companies in the pipeline as of June 30 [6] - Foreign investors show strong interest in Chinese technology and new consumer enterprises, contributing to the high demand for IPOs in Hong Kong [8][10] Group 3 - The favorable policy environment and market conditions have facilitated the surge in IPOs, with new regulations enhancing the attractiveness of the Hong Kong market for international capital [5][9] - The "A+H" model is becoming a standard for large enterprises, providing strategic advantages such as risk diversification and access to a broader range of financing tools [9][10] - The trend of Chinese consumer companies seeking to list in Hong Kong is driven by the market's strong performance and the opportunity to connect with international capital [10]

Group 1 - The Hong Kong IPO market experienced a significant surge in the first half of 2025, with 40 IPOs raising a total of HKD 1,067.13 billion, marking a year-on-year increase of 688.54% and positioning Hong Kong as the leading global capital market [2][11] - Major contributors to the fundraising included leading A-share companies such as CATL, Hengrui Medicine, and Haitian Flavoring, which collectively raised over HKD 718 billion, accounting for 67% of the total [2][3] - The average fundraising amount per IPO was HKD 26.68 billion, with CATL setting a record with approximately HKD 410 billion, making it the largest IPO globally [2][3] Group 2 - The "A+H" dual-platform listing model has become a prominent trend, with over 40 A-share companies, including Sanhua Intelligent Control and Mixue Group, queuing for listings on the Hong Kong Stock Exchange, primarily in sectors like new energy, pharmaceuticals, and technology [3][6] - Hard technology companies are particularly favored by investors, with firms like Yujing Technology and Horizon Robotics showing strong stock performance and increasing market capitalization [3][7] - The rise of new consumption brands, such as Gu Ming and Mixue Group, reflects the resilience of the domestic market and the ability of these brands to meet the demands of younger consumers [3][7] Group 3 - Chinese investment banks dominate the IPO landscape, with CICC, CITIC Securities, and Huatai Financial Holdings leading in the number of sponsorships, collectively holding a market share of 37.5% [4] - Major projects like CATL and Hengrui Medicine were co-sponsored by both Chinese and foreign investment banks, showcasing the international service capabilities of Chinese institutions [4] Group 4 - The Hong Kong IPO market is expected to maintain its momentum in the second half of 2025, with significant contributions anticipated from the technology, media, telecommunications, and consumer sectors [5][9] - Over 170 listing applications are currently being processed, with five companies potentially raising over USD 1 billion each [5][9] - The successful implementation of the "Science and Technology Enterprise Special Line" and the diversification of international capital allocation are expected to reinforce Hong Kong's position as a leading global listing platform [5][9] Group 5 - The "A+H" listing strategy is driven by policy support and globalization, with regulatory improvements facilitating faster approval processes for eligible A-share companies [6][9] - The approval time for companies like CATL has been reduced to 25 days, significantly shorter than the traditional six-month process [6][9] - Enhanced regulatory cooperation between mainland and Hong Kong authorities has lowered compliance costs, encouraging more industry leaders to list in Hong Kong [6][9] Group 6 - The IPO market in Hong Kong is characterized by a dual-driven model of hard technology and new consumption, with significant participation from sectors such as biotechnology, retail, and telecommunications [7][9] - The energy equipment, electronics, and biopharmaceutical sectors account for over 51% of the IPOs, with a notable focus on sub-sectors like semiconductors and batteries [7][9] - The "A+H" strategy aims to connect international capital with companies looking to expand globally, as seen with companies like Dongpeng Beverage targeting Southeast Asian markets [7][9] Group 7 - Institutional investors in Hong Kong account for over 70% of the market, focusing on fundamental value and long-term prospects, which provides a stable valuation anchor for leading A-share companies [8][9] - The fundraising scale for Chinese companies in Hong Kong reached HKD 592.33 billion in the first half of 2025, with 90% of this amount coming from "A+H" companies [8][9] - International capital is increasingly flowing into the Hong Kong market, with significant participation from sovereign funds and pension funds in IPOs [8][9]

Group 1 - The market has experienced different phases since 2025, with geopolitical changes and advancements in technology, particularly by DeepSeek in the AI sector, being dominant factors [1] - The innovative drug sector has attracted significant investment since May, indicating increased market interest in high-growth industries like biotechnology [1] - Foreign investors are optimistic about the Chinese market, and domestic institutions are confident in the A-share market for the second half of the year, suggesting a potential upward trend after initial fluctuations [1] Group 2 - Goldman Sachs has identified ten leading Chinese companies that are expected to attract foreign investment in the Hong Kong stock market, highlighting their strong market positions and technological advancements [4] - The selected companies represent both the internet technology sector (Tencent, Alibaba, Meituan, NetEase, Ctrip) and traditional manufacturing (BYD, Midea, Anta), all of which have integrated technology into their operations [4] - These ten companies are industry leaders with significant influence, and their listing in Hong Kong facilitates foreign investment compared to the A-share market [4]

【环球网财经综合报道】上半年正式收官，港股IPO市场热度持续攀升。数据显示，今年上半年港交所完成43宗IPO项目，同比增加13家，增幅 43.33%；募资总额达1067.13亿港元，较去年同期增长688.54%，超2024年全年募资额。 谈及港股IPO火热原因，高盛亚洲相关人士指出，中国经济刺激政策带动全球投资者关注中国资产，监管支持力度大，上市企业质量高。中信证 券研报预计，A股公司港股发行潮或在2025年下半年，多家A股上市公司将分拆子公司赴港上市。 展望下半年，德勤预计2025年全年香港新股市场80只新股融资2000亿港元，除25只"A+H"新股外，多数项目来自科技、传媒、电信及消费业。德 勤相关负责人表示，若无重大负面干扰，对香港2025年争取全球IPO市场领先地位持审慎乐观态度。（陈十一） 从单个项目募资规模看，募资超100亿港元的IPO项目有宁德时代、恒瑞医药、海天味业3家；募资20亿至100亿港元的有三花智控等5家。 港交所上市通道迎来申报热潮，截至6月30日，220家企业处于IPO排队状态，较2024年同期显著增长，仅6月27日就有16家内地企业递表申请主板 上市，其中科技行业占10家。 "A ...

Summary of Conference Call Records Industry Overview - The innovative drug industry chain is gradually stabilizing and recovering, with CXO orders rebounding since last year, leading to strong mid-year performance in key segments [1][2][3] - The overall trend for the pharmaceutical sector in Q2 2025 is positive, particularly in innovative drugs and their supply chains, despite recent market fluctuations [2][3] Key Companies and Performance - **Hengrui, Huadong, and China Biopharmaceutical** are expected to achieve double-digit growth in Q2 and for the entire year [1][6] - **WuXi AppTec** aims for a revenue target of 43 billion, with an expected growth of over 15% and faster net profit growth; **WuXi AppTec's** revenue growth is projected at over 35% for the year [1][11] - **Kelaiying** anticipates a revenue growth of over 15% for the year, while **Kanglong Huacheng** expects around 10% growth in revenue and profit for Q2 [1][11][13] - **BaiPuSi and Haoyuan Pharmaceutical** are performing well, with most companies expecting revenue growth of over 20% [1][15] Market Catalysts - Recent adjustments in medical insurance policies and industry conferences (WCLC, ESMO, Ash) are seen as potential catalysts for growth in the innovative drug sector [1][7][9] - The upcoming medical insurance negotiations and directory adjustments are expected to be significant driving forces in the second half of the year [9][10] Investment Opportunities - Despite a recent decline in market sentiment, large-cap companies like **BaiJi, Hengrui, XinDa, Kangfang, and Shiyao** are recommended for investment, along with smaller companies like **Dizhe and Yifangzejin** [10] - The CXO and upstream sectors are highlighted as key investment areas, with strong performance expected due to improved orders and geopolitical factors [19][20] Sector Performance - The medical device sector is still in a clearing inventory phase, with some companies showing good growth, particularly in overseas markets [17][18] - The OTC and traditional Chinese medicine sectors have not shown significant improvement but may see recovery in the second half of the year [5][18] Future Outlook - The overall outlook for the second half of 2025 remains optimistic, with expectations of continued growth in the innovative drug sector and supportive external factors [9][24] - The domestic financing environment is expected to improve, with a notable increase in activity anticipated in the latter half of the year [26][38] Conclusion - The innovative drug industry chain, particularly the CXO segment, is positioned for strong growth, supported by favorable market conditions and strategic company performances. Investors are encouraged to focus on key players within this sector for potential opportunities.

Group 1: Index and Market Trends - The Hang Seng Hong Kong Stock Connect Innovative Drug Index will be revised to exclude CXO companies, focusing solely on innovative drug firms, achieving a 100% purity in its index composition [1] - This adjustment is expected to increase the weight of Hong Kong innovative drug companies in the index, better reflecting the core trends and valuation logic of the innovative drug industry [1] Group 2: Company Developments - Heng Rui Medicine received approval from the National Medical Products Administration for its innovative drug SHR0302 for treating severe alopecia areata, marking a significant advancement in domestic JAK1 inhibitors [2] - The approval addresses a substantial patient population in China, with approximately 3.49 million alopecia areata patients reported in 2021, highlighting the unmet medical need in this area [2] - Huiyu Pharmaceutical's TCE tri-antibody drug HY05350 has received clinical trial approval for treating advanced solid tumors, showcasing the company's capabilities in innovative drug development [3] - Han Yu Pharmaceutical expects a net profit of 142 to 162 million yuan for the first half of 2025, driven by strong global market demand and successful product approvals, indicating a recovery from previous losses [4] - The company's performance is significantly influenced by a few products in overseas markets, raising questions about future sustainability [4]

Group 1 - The Hong Kong IPO market has shown significant growth in the first half of 2025, with 43 IPOs completed, a 43.33% increase from the same period last year, and total fundraising reaching HKD 1,067.13 billion, up 688.54% year-on-year [1][4] - Notable IPOs include CATL, Hengrui Medicine, and Haitian Flavoring, each raising over HKD 10 billion, while five other companies raised between HKD 2 billion and HKD 10 billion [1][4] - As of June 30, 2025, there are 220 companies in the IPO queue, indicating strong market vitality compared to only 80 applications reviewed in the previous year [1][3] Group 2 - The surge in IPOs is attributed to supportive regulatory policies, improved market liquidity, and the high quality of companies going public, with a notable increase in the success rate of IPO projects [8][9] - The "A+H" listing trend continues to rise, with several A-share companies successfully listing in Hong Kong, contributing significantly to the total fundraising amount [3][9] - Deloitte forecasts that the Hong Kong IPO market could raise HKD 200 billion through 80 new listings in 2025, with a focus on technology, media, telecommunications, and consumer sectors [9]

Core Viewpoint - The Hong Kong IPO market has experienced explosive growth in the first half of this year, with a significant increase in the number of IPOs and total financing amount compared to the same period last year [1][2]. Group 1: IPO Market Performance - From January 1 to June 30, 2023, there were 43 IPOs on the Hong Kong Stock Exchange, an increase of 13 compared to the same period last year [1]. - The total IPO financing amount reached 1,067.13 billion HKD, surpassing the total financing amount of 881.47 billion HKD for the entire previous year, representing a year-on-year increase of 688.56% [1]. - Hong Kong Stock Exchange ranked first globally in terms of IPO financing scale [1]. Group 2: Industry Distribution of IPOs - The majority of IPOs in the first half of 2023 came from industries such as electrical equipment, pharmaceutical and biotechnology, food and beverage, machinery, consumer services, non-ferrous metals, software services, and banking, with new consumption and technology companies being predominant [1]. - The top three industries in terms of fundraising were electrical equipment (426.44 billion HKD), pharmaceutical and biotechnology (156.30 billion HKD), and food and beverage (116.01 billion HKD) [1]. Group 3: Notable IPOs - Among the 43 IPOs, 17 companies raised over 1 billion HKD, 8 companies raised over 2 billion HKD, and 6 companies raised over 3 billion HKD [1]. - The top three companies by IPO financing were Ningde Times (410.06 billion HKD), Hengrui Medicine (113.74 billion HKD), and Haitian Flavoring and Food (101.29 billion HKD) [1]. - Other companies with IPO financing exceeding 2 billion HKD included Sanhua Intelligent Control, Mixue Group, Chifeng Jilong Gold Mining, Nanshan Aluminum International, and Guming [1]. Group 4: A-Share Companies Listing in Hong Kong - There has been a noticeable increase in A-share companies listing in Hong Kong this year, with several companies such as Ningde Times, Hengrui Medicine, and Haitian Flavoring and Food already listed [2]. - The trend of "A+H" listings is expected to be a key theme for 2025, with over 30 A-share companies having submitted applications for H-share listings and more than 20 companies announcing plans for H-share listings [2].